Announcement: Live biotherapeutic matches donor FMT in treating recurrent C. diff infection

GMJ
By
Prof. Giorgi Pkhakadze
0 Min Read
Medical illustration comparing manufactured biotherapeutic capsules to traditional fecal microbiota transplant procedure
Phase 1b trial shows manufactured 15-strain biotherapeutic achieves similar efficacy to traditional fecal transplant in treating recurrent C. difficile infection. Both treatments demonstrated 85-90% success rates. — Photo: National Institute of Allergy and Infectious Diseases / Pexels
1 min read|40 words

Breakthrough: Manufactured 15-strain biotherapeutic achieves 85-90% success rate matching traditional fecal transplant for recurrent C. diff infections. Phase 1b trial shows standardized microbiome therapy could offer safer, scalable alternative to whole stool FMT.

Read the full article on GMJ Newsroom →

Was this article helpful?

Share This Article
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Mobile Phone Surveys Show Promise as Supplement to Traditional Mortality Surveillance in Bangladesh

Research published in Tropical Medicine & International Health shows mobile phone surveys…

Taiwan develops algorithm to identify pregnancies and estimate gestational age from health records

Researchers in Taiwan developed a hierarchical algorithm to identify pregnancies and estimate…

Emotion Regulation and Body Image: Psychological Distress Emerges as a Key Link in Lebanese Adults

A cross-sectional study of 682 Lebanese adults reveals that psychological distress significantly…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like